1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
TTY Biopharm Company Limited

TTY Biopharm Company Limited

TTPEX:4105
80.60
TWD
-0.40
(-0.49%)
18.82BMarket Cap
Oct 30Next Earn
TTY Biopharm Company Limited
TPEX:4105
(Taipei Exchange)

Recent

price

80.60

P/E

ratio

- -

div

yld

-0.18%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
17.06
19.3
17.59
13.35
11.98
12.85
15.12
16.4
16.23
17.96
16.98
18.24
20.36
22.14
23.7
25.95
- -
Revenue per Share
1.81
2.6
2.35
2.52
3.14
4.87
4.8
5.41
5.88
3.62
3.72
3.35
4.4
4.54
5.83
6.27
- -
Basic EPS, GAAP
-0.57
-1.14
-0.95
0.21
-0.44
1.83
4.52
3.62
3.97
4.58
1.39
4.75
4.42
3.96
4.89
6.48
- -
Free Cash Flow per Basic Share
1.48
0.34
0.58
1.29
1.87
2.5
3.5
3.8
4.5
4.5
4
4
3
3.4
3.5
4.2
-0.14
Dividend per Share
8.7
11.07
14
15.59
16.87
20.52
21.63
22.11
23.34
22.4
21.92
20.78
22.76
23.89
27.15
29.11
27.97
Book Value per Share
8.46
10.78
13.73
15.24
16.61
20.31
21.51
21.53
22.73
21.84
21.38
20.28
21.75
23.23
25.65
27.4
25.66
Tangible Book Value per Share
201
201
228
233
249
249
249
249
249
249
249
249
249
249
249
249
249
Basic Weighted Avg Shares
3,438
3,871
4,016
3,110
2,980
3,195
3,761
4,079
4,036
4,466
4,222
4,536
5,062
5,506
5,894
6,453
- -
Sales/Revenue/Turnover
15.92
14.08
16.26
10.93
11.35
24.72
31.37
30.82
26.11
27.39
22.62
25.48
24.34
24.98
23.65
26.42
- -
Operating Margin (%)
96
109
124
102
124
119
123
141
146
152
157
167
186
201
202
197
- -
Depreciation Expense
365
522
537
587
780
1,211
1,193
1,345
1,461
900
924
832
1,094
1,129
1,450
1,559
- -
Net Income, GAAP
22.24
20.47
22.22
22.93
10.79
18.29
17.02
14.22
12.34
24.52
18.55
24.35
21.67
21.2
19.43
22.14
- -
Effective Tax Rate (%)
10.62
13.49
13.36
18.89
26.16
37.9
31.73
32.97
36.21
20.15
21.89
18.34
21.62
20.5
24.6
24.16
- -
Profit Margin (%)
1,059
520
1,151
503
161
2,232
2,388
2,214
2,683
1,949
2,250
1,698
2,118
2,787
2,931
3,369
3,414
Working Capital
- -
- -
- -
- -
- -
700
630
250
350
16
412
18
13
403
110
7
405
LT Debt
2,649
3,444
4,413
4,328
4,632
5,695
6,010
6,112
6,392
6,169
6,078
5,767
6,233
6,506
7,511
8,051
7,749
Total Equity
13.25
9.69
9.08
4.33
4.8
9.02
12.15
12.83
11.24
11.62
9.65
10.56
11.83
12.98
12.53
13.99
- -
Return on Invested Capital (%)
9.33
9.07
7.43
9.08
12.38
17.08
14.64
16.3
18.14
11.55
11.09
10.56
13.74
14.12
15.95
16.1
- -
Return on Capital (%)
17.45
21.24
17.22
15.97
19.32
26.05
22.77
24.73
25.86
15.83
16.77
15.67
20.22
19.46
22.84
22.29
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,218
1,028
1,660
LT Borrowings
- -
- -
400
LT Finance Leases
7
6
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
249
249
249
Market Capitalization
20,265
18,102
18,823

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,009
6,187
6,430
Cash, Cash Equivalents & STI
2,989
3,307
3,377
Accounts Receivable, Net
1,495
1,328
1,375
Inventories
1,389
1,406
1,392
Total Current Liabilities
2,640
3,621
3,017
Payables & Accruals
- -
- -
- -
ST Debt
1,218
1,028
1,660
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.68%
6%
7.19%
Free Cash Flow
36.45%
56.34%
32.58%
Net Income, GAAP
4.48%
12.14%
7.55%
Sales/Revenue/Turnover
7.46%
8.87%
9.49%
Total Cash Common Dividend
- -
- -
20%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,274
1,375
1,533
1,712
5,894
2025
1,459
1,512
- -
1,662
6,453
2026
1,520
1,652
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.13
1.05
1.5
2.15
5.83
2025
1.57
1.14
- -
1.22
6.27
2026
1.78
1.63
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.09
-0.09
3.5
2025
- -
- -
- -
-0.14
4.2
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
TTY Biopharm Company Limited, along with its associated entities, specializes in the research, development, manufacturing, and commercialization of advanced pharmaceutical and chemical products across Taiwan and international markets. The enterprise is structured around key operational divisions, including its Oncology Business, Intensive Care Business, Healthcare Business, and an Export and Contract Development and Manufacturing Organization (CDMO) Business. The company delivers a diverse portfolio of oncology medications, encompassing anti-cancer therapies and supportive care treatments. In the anti-infection realm, it offers critical anti-infective agents and influenza vaccines, such as the recently launched antibiotic, Bobimixyn. Furthermore, TTY Biopharm provides a range of healthcare-focused products addressing digestive health, bone density, and metabolic conditions. Key offerings also include innovative drugs developed using advanced liposome and microsphere technologies, such as Lipo-AB, which is expanding in the U.S. market, and the blood cancer therapy Minjuvi, approved in early 2025. Beyond its core pharmaceutical lines, the company is actively involved in the sale of functional foods and undertakes global import and export trade, alongside strategic investment activities. TTY Biopharm leverages its robust research and development capabilities to create specialized formulations and novel drugs, aiming to address unmet medical needs. The company reported strong financial results for the third quarter and nine months ended September 30, 2025, with increased sales and net income. Established in 1960, TTY Biopharm Company Limited maintains its headquarters in Taipei, Taiwan.